Buprenorphine

(asked on 14th March 2025) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what data his Department holds on the availability of Buvidal, broken down by region.


Answered by
Ashley Dalton Portrait
Ashley Dalton
Parliamentary Under-Secretary (Department of Health and Social Care)
This question was answered on 21st March 2025

Ministers in the Department of Health and Social Care and the Ministry of Justice have discussed the issue. The Department of Health and Social Care advises local areas that they can use the funding given to them to deliver drug and alcohol treatment to enable prescribing of buprenorphine long-acting injection in their areas, and advises and supports local areas to establish, maintain and grow this provision and this includes for those who leave prison.

It is a clinical decision whether to offer this treatment, based on an individual assessment and personal choice. Buvidal is available in all regions in England; the following table shows its availability in community structured treatment as a proportion of the overall population in treatment for opiate use, broken down by region, for the fourth quarter of 2023/24, the latest period for which data is available:

Region

Adults in treatment for opiates

Buprenorphine long lasting injection

Buprenorphine long lasting injection (%)

East Midlands

11619

184

1.58%

East of England

10886

226

2.08%

London

17630

686

3.89%

North East

10121

329

3.25%

North West

24116

939

3.89%

South East

14485

282

1.95%

South West

13371

288

2.15%

West Midlands

16666

342

2.05%

Yorkshire & the Humber

18355

529

2.88%

England

137249

3805

2.77%

Source: National Drug Treatment Monitoring System March 2024

Reticulating Splines